Erasca Receives FDA Fast Track Designation for ERAS-0015 in Metastatic Pancreatic Adenocarcinoma

Erasca, Inc. (ERAS) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ERAS-0015 for the treatment of patients with metastatic pancreatic adenocarcinoma. This designation aims to facilitate development and expedite the review of therapies addressing serious conditions with unmet medical needs.